Sayuk, G. S., J. E. Elwing, and M. Lisker-Melman. 2007. Hepatic glycogenosis: An underrecognized source of abnormal liver function tests? Digestive Diseases and Sciences 52:936–938.
Temple, R. 2001. Hepatotoxicity through the years: Impact on the FDA. www.fda.gov/cder/livertox/meeting2001.htm#Drug-Induced (accessed October 17, 2008).
Thulin, P., I. Rafter, K. Stockling, C. Tomkiewicz, E. Norjavaara, M. Aggerbeck, H. Hellmold, E. Ehrenborg, U. Andresson, I. Cotgreave, and B. Glinghammar. 2008. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes. Toxicology and Applied Pharmacology 231(1):1–9.
Uetrecht, J. 2007. Idiosyncratic drug reactions: Current understanding. Annual Review of Pharmacology and Toxicology 47:513–539.
Watkins, P. B. 1998. Hepatic dysfunction associated with troglitazone. New England Journal of Medicine 338:916–917.
Watkins, P. B., H. J. Zimmerman, M. J. Knapp, S. I. Gracon, and K. W. Lewis. 1994. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. Journal of the American Medical Association 271(13):992–998.
Watkins, P. B., P. J. Seligman, J. S. Pears, M. I. Avigan, and J. R. Senior. 2008. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology 48(5):1680–1689.
Wilke, R. A., D. W. Lin, D. M. Roden, P. B. Watkins, D. Flockhart, I. Zineh, K. M. Giacomini, and R. M. Krauss. 2007. Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges. Nature Reviews Drug Discovery 7:904–916.
Xu, J. J., P. V. Henstock, M. C. Dunn, A. R. Smith, J. R. Chabot, and D. de Graaf. 2008. Cellular imaging predictions of clinical drug-induced liver injury. Toxicological Sciences 105:97–105.
Zimmerman, H. J. 1968. The spectrum of hepatotoxicity (Kober lecture). Perspectives in Biology and Medicine 12(1)135–161.